Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Approves Vivus’ Obesity Drug, Recommends Against Use In High-Risk Heart Patients

This article was originally published in The Pink Sheet Daily

Executive Summary

A Risk Evaluation and Mitigation Strategy for Qsymia includes prescriber education about the risk of birth defects and limits dispensing to specially certified pharmacies


Related Content

Women’s Intuition: What Approval Of Sprout’s Addyi Means For Sponsors
To Market Qsymia, Vivus Takes On Additional Debt
Orexigen Gives The Skinny On Obesity Market During Contrave Update
REMS vs. Labeling-only Strategy For Teratogenic Drugs Goes Before Advisory Panel
Belviq Gains FDA Approval For Weight Loss, But DEA Review Will Delay Launch
Qnexa REMS Should Deter Off-Label Use Of Components, But Not Place Undue Burden
Panel Favors Qnexa Approval, Given Strong Efficacy, Certainty Of Post-Approval CV Study
Orexigen Agreement On Contrave CV Trial Hints At FDA’s Thinking On Obesity
Vivus' Qnexa Gets "Complete Response" Letter From FDA
Qnexa Proposed REMS Focuses On Registry, Web-Based Physician Education


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts